Chemfab Alkalis Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 12, 2025, 12:02 pm

Quick Insight

Chemfab Alkalis Ltd, operating in the caustic soda and soda ash sector, presents a mixed investment profile. With a market capitalization of ₹1,110 crore and a current share price of ₹773, the stock carries a high Price-to-Earnings (P/E) ratio of 73.0, indicating potential overvaluation given its modest Return on Equity (ROE) of 3.80% and Return on Capital Employed (ROCE) of 5.91%. The company’s Operating Profit Margin (OPM) stands at 17.86%, which is commendable, yet the net profit of ₹15 crore raises concerns about profitability sustainability. Notably, the promoter holding is robust at 72.56%, suggesting confidence from management. However, with a Price-to-Book Value (P/BV) of 2.38x and a low interest coverage ratio (ICR) of 66.27x, investors should exercise caution. The company's negative cash conversion cycle (CCC) of -20 days is a positive indicator of operational efficiency. Overall, while Chemfab Alkalis exhibits operational strengths, the elevated valuation metrics warrant a cautious approach for new investors.

Competitors of Chemfab Alkalis Ltd

All Competitor Stocks of Chemfab Alkalis Ltd

Quarterly Result

Last Updated: August 1, 2025, 10:45 pm

Below is a detailed analysis of the quarterly data for Chemfab Alkalis Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 87.58 Cr.. The value appears to be declining and may need further review. It has decreased from 87.85 Cr. (Mar 2025) to 87.58 Cr., marking a decrease of 0.27 Cr..
• For Expenses, as of Jun 2025, the value is 74.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.16 Cr. (Mar 2025) to 74.16 Cr., marking an increase of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 13.42 Cr.. The value appears to be declining and may need further review. It has decreased from 15.69 Cr. (Mar 2025) to 13.42 Cr., marking a decrease of 2.27 Cr..
• For OPM %, as of Jun 2025, the value is 15.32%. The value appears to be declining and may need further review. It has decreased from 17.86% (Mar 2025) to 15.32%, marking a decrease of 2.54%.
• For Other Income, as of Jun 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 1.27 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 0.21 Cr..
• For Interest, as of Jun 2025, the value is 1.56 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.56 Cr..
• For Depreciation, as of Jun 2025, the value is 5.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.64 Cr. (Mar 2025) to 5.38 Cr., marking a decrease of 4.26 Cr..
• For Profit before tax, as of Jun 2025, the value is 7.54 Cr.. The value appears strong and on an upward trend. It has increased from 5.76 Cr. (Mar 2025) to 7.54 Cr., marking an increase of 1.78 Cr..
• For Tax %, as of Jun 2025, the value is 28.38%. The value appears to be improving (decreasing) as expected. It has decreased from 31.77% (Mar 2025) to 28.38%, marking a decrease of 3.39%.
• For Net Profit, as of Jun 2025, the value is 5.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.93 Cr. (Mar 2025) to 5.39 Cr., marking an increase of 1.46 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.75. The value appears strong and on an upward trend. It has increased from 2.74 (Mar 2025) to 3.75, marking an increase of 1.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:58 am

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 12:18 pm

Below is a detailed analysis of the balance sheet data for Chemfab Alkalis Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
• For Reserves, as of Mar 2025, the value is 393.00 Cr.. The value appears strong and on an upward trend. It has increased from 379.00 Cr. (Mar 2024) to 393.00 Cr., marking an increase of 14.00 Cr..
• For Borrowings, as of Mar 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 20.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 64.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 54.00 Cr.. The value appears to be improving (decreasing). It has decreased from 85.00 Cr. (Mar 2024) to 54.00 Cr., marking a decrease of 31.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 546.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 498.00 Cr. (Mar 2024) to 546.00 Cr., marking an increase of 48.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 249.00 Cr.. The value appears strong and on an upward trend. It has increased from 181.00 Cr. (Mar 2024) to 249.00 Cr., marking an increase of 68.00 Cr..
• For CWIP, as of Mar 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2024) to 12.00 Cr., marking a decrease of 45.00 Cr..
• For Investments, as of Mar 2025, the value is 164.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2024) to 164.00 Cr., marking an increase of 54.00 Cr..
• For Other Assets, as of Mar 2025, the value is 121.00 Cr.. The value appears to be declining and may need further review. It has decreased from 150.00 Cr. (Mar 2024) to 121.00 Cr., marking a decrease of 29.00 Cr..
• For Total Assets, as of Mar 2025, the value is 546.00 Cr.. The value appears strong and on an upward trend. It has increased from 498.00 Cr. (Mar 2024) to 546.00 Cr., marking an increase of 48.00 Cr..

Notably, the Reserves (393.00 Cr.) exceed the Borrowings (84.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Chemfab Alkalis Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 24, the value is 18.53. This value is within the healthy range. It has decreased from 45.61 (Mar 23) to 18.53, marking a decrease of 27.08.
• For Diluted EPS (Rs.), as of Mar 24, the value is 18.34. This value is within the healthy range. It has decreased from 45.14 (Mar 23) to 18.34, marking a decrease of 26.80.
• For Cash EPS (Rs.), as of Mar 24, the value is 34.21. This value is within the healthy range. It has decreased from 61.71 (Mar 23) to 34.21, marking a decrease of 27.50.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 271.92. It has increased from 254.72 (Mar 23) to 271.92, marking an increase of 17.20.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 271.92. It has increased from 254.72 (Mar 23) to 271.92, marking an increase of 17.20.
• For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 230.06. It has decreased from 233.65 (Mar 23) to 230.06, marking a decrease of 3.59.
• For PBDIT / Share (Rs.), as of Mar 24, the value is 43.89. This value is within the healthy range. It has decreased from 81.79 (Mar 23) to 43.89, marking a decrease of 37.90.
• For PBIT / Share (Rs.), as of Mar 24, the value is 28.18. This value is within the healthy range. It has decreased from 65.62 (Mar 23) to 28.18, marking a decrease of 37.44.
• For PBT / Share (Rs.), as of Mar 24, the value is 27.52. This value is within the healthy range. It has decreased from 63.06 (Mar 23) to 27.52, marking a decrease of 35.54.
• For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 45.54 (Mar 23) to 18.50, marking a decrease of 27.04.
• For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 45.54 (Mar 23) to 18.50, marking a decrease of 27.04.
• For PBDIT Margin (%), as of Mar 24, the value is 19.07. This value is within the healthy range. It has decreased from 35.00 (Mar 23) to 19.07, marking a decrease of 15.93.
• For PBIT Margin (%), as of Mar 24, the value is 12.24. This value is within the healthy range. It has decreased from 28.08 (Mar 23) to 12.24, marking a decrease of 15.84.
• For PBT Margin (%), as of Mar 24, the value is 11.96. This value is within the healthy range. It has decreased from 26.99 (Mar 23) to 11.96, marking a decrease of 15.03.
• For Net Profit Margin (%), as of Mar 24, the value is 8.04. This value is within the healthy range. It has decreased from 19.49 (Mar 23) to 8.04, marking a decrease of 11.45.
• For NP After MI And SOA Margin (%), as of Mar 24, the value is 8.04. This value is within the healthy range. It has decreased from 19.49 (Mar 23) to 8.04, marking a decrease of 11.45.
• For Return on Networth / Equity (%), as of Mar 24, the value is 6.80. This value is below the healthy minimum of 15. It has decreased from 17.87 (Mar 23) to 6.80, marking a decrease of 11.07.
• For Return on Capital Employeed (%), as of Mar 24, the value is 9.81. This value is below the healthy minimum of 10. It has decreased from 25.41 (Mar 23) to 9.81, marking a decrease of 15.60.
• For Return On Assets (%), as of Mar 24, the value is 5.26. This value is within the healthy range. It has decreased from 15.67 (Mar 23) to 5.26, marking a decrease of 10.41.
• For Long Term Debt / Equity (X), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 23) to 0.04, marking an increase of 0.04.
• For Total Debt / Equity (X), as of Mar 24, the value is 0.04. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.04, marking an increase of 0.04.
• For Asset Turnover Ratio (%), as of Mar 24, the value is 0.71. It has decreased from 0.86 (Mar 23) to 0.71, marking a decrease of 0.15.
• For Current Ratio (X), as of Mar 24, the value is 1.09. This value is below the healthy minimum of 1.5. It has decreased from 2.71 (Mar 23) to 1.09, marking a decrease of 1.62.
• For Quick Ratio (X), as of Mar 24, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 2.34 (Mar 23) to 0.92, marking a decrease of 1.42.
• For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.47. This value is within the healthy range. It has increased from 3.36 (Mar 23) to 4.47, marking an increase of 1.11.
• For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 6.73. This value is below the healthy minimum of 20. It has increased from 2.73 (Mar 23) to 6.73, marking an increase of 4.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.64. This value is below the healthy minimum of 20. It has increased from 2.01 (Mar 23) to 3.64, marking an increase of 1.63.
• For Earning Retention Ratio (%), as of Mar 24, the value is 93.27. This value exceeds the healthy maximum of 70. It has decreased from 97.27 (Mar 23) to 93.27, marking a decrease of 4.00.
• For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.36. This value exceeds the healthy maximum of 70. It has decreased from 97.99 (Mar 23) to 96.36, marking a decrease of 1.63.
• For Interest Coverage Ratio (X), as of Mar 24, the value is 66.27. This value is within the healthy range. It has decreased from 473.83 (Mar 23) to 66.27, marking a decrease of 407.56.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 28.94. This value is within the healthy range. It has decreased from 278.63 (Mar 23) to 28.94, marking a decrease of 249.69.
• For Enterprise Value (Cr.), as of Mar 24, the value is 916.08. It has increased from 314.58 (Mar 23) to 916.08, marking an increase of 601.50.
• For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.80. This value is within the healthy range. It has increased from 0.94 (Mar 23) to 2.80, marking an increase of 1.86.
• For EV / EBITDA (X), as of Mar 24, the value is 14.67. This value is within the healthy range. It has increased from 2.71 (Mar 23) to 14.67, marking an increase of 11.96.
• For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.82. This value is within the healthy range. It has increased from 0.96 (Mar 23) to 2.82, marking an increase of 1.86.
• For Retention Ratios (%), as of Mar 24, the value is 93.26. This value exceeds the healthy maximum of 70. It has decreased from 97.26 (Mar 23) to 93.26, marking a decrease of 4.00.
• For Price / BV (X), as of Mar 24, the value is 2.38. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 2.38, marking an increase of 1.50.
• For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.82. This value is within the healthy range. It has increased from 0.96 (Mar 23) to 2.82, marking an increase of 1.86.
• For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.20 (Mar 23) to 0.02, marking a decrease of 0.18.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness